Abionyx Pharma (LTS:0RAG) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAG Abionyx Pharma LTS:0RAG
29 GF Score
Price €1.86
GF Value €0.85
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0RAG
29GF Score
Abionyx Pharma LTS:0RAG
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Abionyx Pharma (LTS:0RAG) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €1.86 is trading 118.8% above its estimated GF Value™ of €0.85. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for LTS:0RAG:

  • Short Ratio:
  • GF Value™: €0.85 vs. price of €1.86 (118.8% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the LTS:0RAG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Other Exchanges ABNX:France609:Germany
Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
29GF Score

Get the complete analysis for LTS:0RAG

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.86
Price
€0.85
GF Value